Editorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE
|
|
- Sherman Perkins
- 6 years ago
- Views:
Transcription
1 Editorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE Patients who survive an episode of sustained ventricular trachycardia (VT) or out-of-hospital ventricular fibrillation (VF) are known to have a high recurrence rate of 10% to 20% at 2 years.' Until the early 1990s, the preferred therapy for this high-risk population remained unclear. A variety of therapies have been proposed, including serial drug testing guided by Holter monitor or eletrophysiologic study, empiric amiodarone, direct surgical ablation, electrophysiology-guided amiodarone therapy, and implantable cardioverter defibrillator (lcd).2-7 Despite its proven efficacy in preventing recurrent sudden cardiac death (SCD), the ICD was not subjected to a prospective randomi.zed trial against other effective therapies until recently. Many electrophysiologists thought that such a trial would be unethical because it would withhold obviously effective therapy from high-risk patients. But the continued miniaturization and case of implantation of the lcd, coupled with its high price and the widening infl~ence of managed case which resisted this costly therapy, made such trials inevitable. It became clear in the early 1990s that detailed definition of the efficacy and relative cost of the ICD was necessary to justify both its expanding implantation and its cost. Very recently, a few important clinical trials have provided information about the management of patients who survived an episodes of SCD. The debate as to whether anti-arrhythmic therapy was best guided by Holter monitoring or invasive electrophysiologic study (EPS) led to the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. 8.9 In this trial, 486 patients who had been resuscitated trom sudden cardiac death or electrocardiographically documented VT or unmonitored syncope, were randomized Holterversus EPS-guided treatment, with imipramin, mexiletine, procainamide, quinidine, sotalol, pirmenol or propafenone. In the Holter limb, drug efficacy was defined as 100% suppression of VT runs> IS beats, 80% suppression of pairs, and 70% suppression of PVCs. Electrophysiologic study efficacy was defined as suppression of the VT inducibility (no VT induced > IS beats in duration). The primary endpoint was recurrence of arrhythmia in a patient receiving a drug predicted to be effective by serial testing. Secondary endpoints included death trom any cause, death trom cardiac cause, and death from arrhythmia. Of 242 electrophysiologic study limb patients, 108 (45%) achieved efficacy, whereas 187 (77%) of 244 Holter monitoring patients achieved efficacy. There was no statistical difference (P = 0.69) between the two techniques in predicting arrhythmia recurrence (58% recurrence rate at 2 years).9 Compared with other drugs tested, sotalol had a statistically lower recurrence rate of arrhythmia (P < 0.001), death trom any cause (P < 0.004), death trom cardiac cause (P < 0.02), and death trom arrhythmia (P = 0.04).10 The main finding of ESVEM was that Holter monitoring was equally predictive of arrhythmia recurrence, when compared with serial electrophysiologic testing. In the author's perspective, the high 2-year arrhythmia recurrence rates utilizing both techniques, suggest that serial testing, using either method has limited value in this patient population. The higher efficacy of sotalol may be secondary to a combination of its beta-blocker and Class III antiarrhythmic effects. Recent data from ESVEM II demonstrated that arrhythmia recurrence of Class I patients plus a beta-blocker was similar to sotalol, and both were better that Class I agents without a betablocker. Although sotalol appeared more effective than the other drugs in this study, the lack of a placebo group limits this interpretation. The results ofesvem are limited by the fact that patients were required to have both frequent PVCs and inducible VT. Previous studies have shown that these findings are relevant to < 35% of the sustained VTNF population. 12
2 2 The Cardiac Arrest Study in Seattle: Conventional versus Amiodarone Drug Evaluation (CASCADE)13 evaluated antiarrhythmia drug treatment of 228 survivors of out-of-hospital VF not associated with a Q wave MI. Patients qualified if they had ~ 10 PVCs/ h on Holter, and had inducible sustained VT or VF. Patients were randomized to empiric treatment with amiodarone (n = 113) or electrophysiologic studyguided treatment (n = 115), using conventional antiarrhythmic therapy (Class I antiarrhythmics). The primary endpoint was cardiac survival. The mean EF of randomized patients was 35%::!:: 10%. Of note, 46% of patients received ICDs. Patients treated with amiodarone had better "cardiac survival" (defined as cardiac mortality, syncope/ics shock, resuscitated cardiac arrest) than the conventional treated group) (P = 0.007). In addition, the amiodarone patients had greater survival free of sustained arrhythmias (P = 0.00 \). There were no significant differences in outcomes between conventionally treated patients whose inducible arrhythmias were or were not suppressed. Amiodarone was associated with a \ 0% 3-year pulmonary toxicity rate. Although amiodarone appeared superior to guided therapy with conventional agents, only 4\ % of the amiodarone groups had no cardiac death or sustained arrhythmia by 6-year followup. Therefore, ICD therapy may be a better alternative to either of the pharmacologic approaches. Given the high recurrence rate in the empiric amiodarone group, serial guided therapy, using amiodarone may provide a more predictive approach when drugs are used without lcds. To compare the efficacy of antiarrhythmia therapy against an ICD in survivors of sudden cardiac death unrelated to MI, the Cardiac Arrest Study, Hamburg (CASH) tria(l4 was initiated. Total mortality was the primary endpoint, with secondary endpoints of hemodynamically unstable VT and incidence of drug withdrawal. Patients were randomized to empiric amiodarone, metoprolol, propafenone, or an ICD within 3 months of their cardiac arrest. Published data from the first 287 patients have shown that the total mortality, although lowest in the ICD section, was similar (about 14%) in the lcd, amiodarone, and metoprolol sections of the study. When compared with the lcd, the propafenone section was associated with significantly higher incidence of total mortality and cardiac arrest recurrence. For that reason the safety monitoring board recommended the deletion of the propafenone treatment limb, and this study is now being continued with amiodarone, metoprolol, and ICD limbs. Enrollment in this trial has recently been completed (n = 349), and findings suggest that the final results are consistent with the interim analyses, except that total mortality was statistically lower (P = 0.047) in the ICD group, compared with the combined metoprolol plus amiodarone-treated groups. The results of CASH suggest that Class I therapy is not as effective as ICD therapy in survivors of cardiac arrest. ICD therapy appears to have a better sudden death and overall survival compared with the antiarrhythmic drugtreated limbs of the study. The potential benefit of a beta-blocker in this study is consistent with beneficial effects noted in other retrospective studies.ls.16 The primary objective of the Antiarrhythmics versus Implantable Defibrillator (AVID) Tria(l7.ls was to determine whether "best" antiarrhythmic therapy (empiric amiodarone or guided sotalol) or ICD therapy is superior in reducing total mortality in patients with a history of sustained VT/VF. Secondary objectives included quality-of-life assessment and costeffectiveness of the two study sections. Of the 1,0 \6 patients (22.2% of the registered group) who were randomized (50% to CD and 50% to antiarrhythmic section), only 2.8% of the drug section was discharged on sotalol; the remaining were treated with amiodarone. Enrollment was stopped prematurely (April 7, \977) because of a significant survival advantage in the ICD group. In the ICD group, 89.3%, 81.6%, and 75.4% survived \,2, and 3 years, respectively, compared with 82.3%,74.7%, and 64.1% in the drug group (P < 0.02). Thus, \-, 2-, and 3-year mortality was reduced by 39%, 27%, and 3\%, respectively, with the majority oficd benefits occurring in the first 9 months. The ICD only extended survival by 2.8 months, although the premature termination of this trial may cause some underestimation of the ICD benefit, and have detrimental effects in any cost-benefit analysis. ICD benefit was most prominent in patients with EF < 35%, with no statistical benefit of the ICD noted in patients with EF > 35%. Patient characteristics were similar in the two treatment groups, except that the ICD group had a lower incidence of prior atrial fibrillation/flutter and Class III CHF patients, and a higher number of patients discharged on a beta-blocker. However, multivariate analysis showed that the beneficial effects of ICD therapy persisted after adjustment of other factors.19.2o The Canadian Implantable Defibrillator Study (CIDS)21 was randomized, multicenter trial comparing the efficacy of ICD therapy (n = 328) to amiodarone
3 2 The Cardiac Arrest Study in Seattle: Conventional versus Amiodarone Drug Evaluation (CASCADE)13 evaluated antiarrhythmia drug treatment of 228 survivors of out-of-hospital VF not associated with a Q wave MI. Patients qualified if they had ~ 10 PVCs/ h on Holter, and had inducible sustained VT or VE Patients were randomized to empiric treatment with amiodarone (n = 113) or electrophysiologic studyguided treatment (n = 115), using conventional antiarrhythmic therapy (Class I antiarrhythmics). The primary endpoint was cardiac survival. The mean EF of randomized patients was 35%:1: 10%. Of note, 46% of patients received ICDs. Patients treated with amiodarone had better "cardiac survival" (defined as cardiac mortality, syncope/ics shock, resuscitated cardiac arrest) than the conventional treated group) (P = 0.007). In addition, the amiodarone patients had greater survival tree of sustained arrhythmias (P = 0.001). There were no significant differences in outcomes between conventionally treated patients whose inducible arrhythmias were or were not suppressed. Amiodarone was associated with a 10% 3-year pulmonary toxicity rate. Although amiodarone appeared superior to guided therapy with conventional agents, only 41 % of the amiodarone groups had no cardiac death or sustained arrhythmia by 6-year followup. Therefore, ICD therapy may be a better alternative to either of the pharmacologic approaches. Given the high recurrence rate in the empiric amiodarone group, serial guided therapy, using amiodarone may provide a more predictive approach when drugs are used without ICDs. To compare the efficacy of anti arrhythmia therapy against an ICD in survivors of sudden cardiac death unrelated to MI, the Cardiac Arrest Study, Hamburg (CASH) triap4 was initiated. Total mortality was the primary endpoint, with secondary endpoints of hemodynamically unstable VT and incidence of drug withdrawal. Patients were randomized to empiric amiodarone, metoprolol, propafenone, or an ICD within 3 months of their cardiac arrest. Published data from the first 287 patients have shown that the total mortality, although lowest in the ICD section, was similar (about 14%) in the lcd, amiodarone, and metoprolol sections of the study. When compared with the lcd, the propafenone section was associated with significantly higher incidence of total mortality and cardiac arrest recurrence. For that reason the safety monitoring board recommended the deletion of the propafenone treatment limb, and this study is now being continued with amiodarone, metoprolol, and ICD limbs. Enrollment in this trial has recently been completed (n = 349), and findings suggest that the final results are consistent with the interim analyses, except that total mortality was statistically lower (P = 0.047) in the ICD group, compared with the combined metoprolol plus amiodarone-treated groups. The results of CASH suggest that Class I therapy is not as effective as ICD therapy in survivors of cardiac arrest. ICD therapy appears to have a better sudden death and overall survival compared with the antiarrhythmic drugtreated limbs of the study. The potential benefit of a beta-blocker in this study is consistent with beneficial effects noted in other retrospective studies.\5.\6 The primary objective of the Antiarrhythmics versus Implantable Defibrillator (AVID) TrialJ7,'8 was to determine whether "best" antiarrhythmic therapy (empiric amiodarone or guided sotalol) or ICD therapy is superior in reducing total mortality in patients with a history of sustained VT/VF. Secondary objectives included quality-of-life assessment and costeffectiveness of the two study sections. Of the 1,016 patients (22.2% of the registered group) who were randomized (50% to CD and 50% to antiarrhythmic section), only 2.8% of the drug section was discharged on sotalol; the remaining were treated with amiodarone. Enrollment was stopped prematurely (April 7, 1977) because of a significant survival advantage in the ICD group. In the ICD group, 89.3%, 81.6%, and 75.4% survived 1,2, and 3 years, respectively, compared with 82.3%,74.7%, and 64.1% in the drug group (P < 0.02). Thus, 1-, 2-, and 3-year mortality was reduced by 39%, 27%, and 31 %, respectively, with the majority of ICD benefits occurring in the first 9 months. The ICD only extended survival by 2.8 months, although the premature termination of this trial may cause some underestimation of the ICD benefit, and have detrimental effects in any costbenefit analysis. ICD benefit was most prominent in patients with EF < 35%, with no statistical benefit of the ICD noted in patients with EF > 35%. Patient characteristics were similar in the two treatment groups, except that the ICD group had a lower incidence of prior atrial fibrillation/flutter and Class III CHF patients, and a higher number of patients discharged on a beta-blocker. However, multivariate analysis showed that the beneficial effects of ICD therapy persisted after adjustment of other factors.'9,2o The Canadian Implantable Defibrillator Study (CIDS)2\ was randomized, multicenter trial comparing the efficacy of ICD therapy (n = 328) to amiodarone
4 3 (n = 331) in 659 patients with prior cardiac arrest or hemodynamically unstable VT. The enrollment criteria included documented VF, out-ofhospital cardiac arrest requiring defibrillation, documented sustained VT ~ 150 beats/min causing presyncope or angina in a patient with an EF::;:; 35%, or syncope with documented spontaneous VT ~ 10 seconds or induced sustained VT. The primary endpoint was to compare these two therapies in reducing arrhythmic death. Secondary endpoints included quality-of-life assessment and cost efficacy analyses, all-cause mortality, nonfatal recurrence of VF, sustained VT causing syncope, or cardiac arrest requiring external cardioversion or defibrillation. Preliminary results suggest that the ICD trended toward overall improvement in survival (P = 0.07), producing a 20% reduction in mortality compared with amiodarone. Many of the ICD patients took beta-blockers, sotalol, and had amiodarone added. The results of CASH, AVID and CIDS support using the ICD as first-line therapy to prolong total and! or sudden death survival in patients at high-risk for sudden death. Future cost efficacy and quality-oflife analysis will help clinicians in prescribing the most effective therapy. The results from these studies have helped clarify the ICD versus antiarrhythmic drug controversy Whether amiodarone would have compared better with the ICD if serial electrophysiologic testing and other predictors of outcome 24 had been used, is not known at this time. Mohammed A. Habbab, FACP, FACC Division of Electrophysiology and Pacing Department of Adult Cardiology Prince Sultan Cardiac Center P.O. Box 7897 (ISO) Riyadh 11159, Saudi Arabia References I. Mitchell LB. Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias.curr Opin Cardiol 1997; 12: Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988;318: Horowitz LN, Josephson ME, Farshidi A, et al. Role of the electrophysiologic study in selection of anfifirrhythmic agents. Circulation 1978;58 : Mason JW, for the electrophysiologic study versus electrocardiographic monitoring investigators. A comparison of electrophysiological testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Eng J Med 1993;329: Winkle RA, Mead RH, Rudes MA, Gaudiani VA, et al. Longterm outcome with the automatic implantable cardioverter defibrillator. JAm CardioI1989;13: Kelly PA, Can nom DS, Garan H, et al. The automati, implantable cardioverter defibrillator: efficacy, complication! and survival in patients with malignant ventriculal arrhythmias. J Am Coli CardioI1988;Il:l Powell AC, Fuchs TE, Finkelstein DM, et al. Influence 01 implantable cardioverter defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88: I The ESVEM Investigators. The ESVEM trial: electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 1989;79: Mason JW, for the ESVEM investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic efficacy for ventricular tachyarrhythmia. N Engl J Med 1993;329: Mason JW, for the ESVEM investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329: II. Reiffel JA, Hahn E, Hartz V, et ai, for the ES VEM investigators. Sotalol for ventricular tachyarrhythmias: Beta-blocking and Class III contributions, and relative efficacy versus Class I drugs after prior drug failure. Am J Cardiol 1997;79: Skale BT, Mils WM, Heger JJ, et al. Survivors of cardiac arrest: prevention of recurrence by drug therapy as predicted by electrophysiologic testing or electrocardiographic monitoring. Am J CardioI1986;57: The CASCADE investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J CardioI1993;72: Siebels J, Cappato R, Ruppel R, et ai, and the CASH investigators. Preliminary results ofthe Cardiac Arrest Study, Hamburg (CASH). Am J CardioI1993;72:109F-13F. 15. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and Am J Cardiol 1991 ;68: Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachycardia. N Engl J Med 1992;327: The AVID investigators. Antiarrhythmics versus Implantable Defibrillators (AVID): rationale, design and methods. Am J CardioI1995;75: The Antiarrhythmics versus Implantable Defibrillators (AVID) investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal xentricular arrhythmias. N Engl J Med 1997;337: Curtis AB, Hollstrom AF, Klein RC, et al. Influence of patient characteristics in the selection of patients for defibrillator implantation (the AVID registry). Am J Cardiol 1997;79:
5 4 20. Kim SG, Hallstom A, Love JC, et ai, for the AVID investigators. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics versus Implantable Detibrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 1997;80: Connolly S, Gent M, Roberts R, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol 1993;72: 103F-8F. 22. Zipes DP. Are the implantable cardioverter defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation 1995;9: Connolly SJ. An AVID dissent: commentary. PACE 1994;17: Naccarelli GV, Fineberg NS, Zipes DP, et al. Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coli Cardiol 1985;6: Journal of the Saudi Heart Association, Vol. 11, No.1, 1999
Arrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationMeta-analysis of the implantable cardioverter defibrillator secondary prevention trials
European Heart Journal (2000) 21, 2071 2078 doi.10.1053/euhj.2000.2476, available online at http://www.idealibrary.com on Meta-analysis of the implantable cardioverter defibrillator secondary prevention
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationSudden cardiac death (SCD) is a
Management of malignant ventricular arrhythmias and cardiac arrest Richard I. Fogel, MD; Eric N. Prystowsky, MD Sudden cardiac death continues to be a major health problem in the United States, accounting
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationDestructive Device Removal - Sparks and Deletion of Therapy History From an Implantable Cardioverter Defibrillator. Case Reports
Case Reports Destructive Device Removal - Sparks and Deletion of Therapy History From an Implantable Cardioverter Defibrillator Takashi Kurita, 1 MD, Shigeyuki Ueda, 2 MD, Hideo Okamura, 2 MD, Takashi
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationManagement of Ventricular Arrhythmias A Trial-based Approach
Journal of the American College of Cardiology Vol. 34, No. 3, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00273-9 REVIEW
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationUse of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications
JACC Vol. 14, No. I July 1 8 1 5 5-61 155 ELECTROPHYSIOLOGIC STUDIES Use of Electrophysiologic Testing in Patients With Nonsustained Ventricular Tachycardia Prognostic and Therapeutic Implications RICHARD
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationThe Multicenter Unsustained Tachycardia Trial (MUSTT)
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial Kerry L. Lee, PhD; Gail Hafley, MS; John D. Fisher, MD; Michael R. Gold, MD; Eric
More informationEvidence for Lidocaine and Amiodarone in Cardiac Arrest Due to VF/Pulseless VT
Evidence for Lidocaine and Amiodarone in Cardiac Arrest Due to VF/Pulseless VT Introduction Evidence supporting the use of lidocaine and amiodarone for advanced cardiac life support was considered by international
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationVentricular tachycardia Ventricular fibrillation and ICD
EKG Conference Ventricular tachycardia Ventricular fibrillation and ICD Samsung Medical Center CCU D.I. Hur Ji Won 2006.05.20 Ventricular tachyarrhythmia ventricular tachycardia ventricular fibrillation
More informationThe patient with electric storm
The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationManagement of Syncope in Heart Failure. University of Iowa
Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationTremendous strides have been made in recent years in the treatment and prevention of
Treatment and Prevention of Sudden Cardiac Death Effect of Recent Clinical Trials Jeffrey J. Goldberger, MD REVIEW ARTICLE Tremendous strides have been made in recent years in the treatment and prevention
More informationJournal of the American College of Cardiology Vol. 34, No. 2, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 2, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00234-X CLINICAL
More informationDevice Update Implantable Cardioverter Defibrillator (ICD) 박상원
2012 년춘계학술대회 Device Update Implantable Cardioverter Defibrillator (ICD) 박상원 Arrhythmia Center, KUMC www.korea-heartrhythm.com Korea University Medical Center Seoul, Korea The Development of ICD by a team
More informationCatheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA
Catheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA Erik Wissner, MD, F.A.C.C. Director - Magnetic Navigation Laboratory
More informationArrhythmias Focused Review. Sustained Ventricular Tachycardia in Ischemic Cardiomyopathy: Current Management
Sustained Ventricular Tachycardia in Ischemic Cardiomyopathy: Current Management Matthew R. Reynolds, MD, MSc, and Mark E. Josephson, MD, Beth Israel Deaconess Medical Center, and Veterans Affairs Health
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationAmiodarone Prescribing and Monitoring: Back to the Future
Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationTachycardias II. Štěpán Havránek
Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia
More informationPause-induced Ventricular Tachycardia: Clinical Characteristics
Pause-induced Ventricular Tachycardia: Clinical Characteristics Margaret Bond A. Study Purpose and Rationale Until three decades ago, ventricular arrhythmias were thought to be rare in occurrence and their
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationIntroduction. CLINICAL RESEARCH Clinical Trial Design. Mohammad Saeed 1 *, Mehdi Razavi 1, Curtis G. Neason 2, and Simona Petrutiu 2. Aims.
Europace (2011) 13, 1648 1652 doi:10.1093/europace/eur195 CLINICAL RESEARCH Clinical Trial Design Rationale and design for programming implantable cardioverter defibrillators in patients with primary prevention
More informationSUDDEN CARDIAC DEATH - A PREDICTABLE, AVOIDABLE AND TREATABLE EVENT? *
Proc. R. Coll. Physicians Edinb. 1998; 29:350-356 SUDDEN CARDIAC DEATH - A PREDICTABLE, AVOIDABLE AND TREATABLE EVENT? * Jennifer Adgey, P.W. Johnston and T.P. Mathew, Regional Medical Cardiology Centre,
More informationThe patient with (without) an ICD and heart failure: Management of electrical storm
ISHNE Heart Failure Virtual Symposium April 2008 The patient with (without) an ICD and heart failure: Management of electrical storm Westfälische Wilhelms-Universität Münster Günter Breithardt, MD, FESC,
More informationThe concept of the implantable cardioverter-defibrillator (ICD) was introduced
Review Rohit Kedia, MD Mohammad Saeed, MD, FACC Implantable Cardioverter-Defibrillators Indications and Unresolved Issues Since the implantable cardioverter-defibrillator was first used clinically in 1980,
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationThe ARREST Trial: Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation
The ARREST Trial: Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation Introduction The ARREST (Amiodarone in out-of-hospital Resuscitation of REfractory Sustained
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationChapter 3. Eur Heart J 2009; 30:
Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Followup of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT) C. Jan Willem Borleffs, MD 1, Lieselot
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationAssessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis
Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department
More informationΕκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης
Εκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης Εμμ. Μ. Κανοσπάκης Καρδιολογική Κλινική Πανεπιζηημίοσ Κρήηης Lessons from large trials Conditioning Rhythm and Electrical Therapy
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationThe Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years
The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years 2001-2003 Alessandro Proclemer, Marco Ghidina*, Gloria Cicuttini*, Dario Gregori*, Paolo
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationImprovements in 25 Years of Implantable Cardioverter Defibrillator Therapy
Neth Heart J (2011) 19:24 30 DOI 10.1007/s12471-010-0047-3 REVIEW ARTICLE - E-LEARNING Improvements in 25 Years of Implantable Cardioverter Defibrillator Therapy G. H. van Welsenes & C. J. W. Borleffs
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Cardioverter- ARBenefits Approval: 09/7/2011 Defibrillators Effective Date: 01/01/2012 Document: ARB0096 Revision Date: Code(s): C1721, C1722, C1777, C1882, C1895, C1896 and C1899
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationReduction in Defibrillator Shocks With an Implantable Device Combining Antitachycardia Pacing and Shock Therapy
JACC Vol. 18, No. I 145 CARDIAC PACING Reduction in Defibrillator Shocks With an Implantable Device Combining Antitachycardia Pacing and Shock Therapy JAMES w. LEITCH, MBBS, ANNE M. GILLIS, MD, D. GEORGE
More informationManagement of Arrhythmias The General Practitioners role
Management of Arrhythmias The General Practitioners role Rohan Gunawardena MD, FRCP, FCCP, FACC Consultant Cardiac Electrophysiologist National Hospital of Sri Lanka Arrhythmias not common Palpitations
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More informationEvaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias. Markus Kowalsky Group 11
Evaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias Markus Kowalsky Group 11 Selected Paper Ventricular arrhythmia is predicted by sum absolute QRST integral but not
More informationNEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS
NEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS OBJECTIVES Discuss history of ICDs Review the indications for ICD and CRT therapy Describe basic lead and device technology Discuss different therapies
More informationPreventive Effect of Amiodarone on VT/VF Events in ICD Patients with Structural Heart Diseases
Original Article Preventive Effect of Amiodarone on VT/VF Events in ICD Patients with Structural Heart Diseases Michiro Kiryu MD, Shinichi Niwano MD, Jun Kishihara MD, Yuya Aoyama MD, Shoko Ishikawa MD,
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationAnti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University
Anti arrhythmic drugs Hilal Al Saffar College of medicine Baghdad University Mechanism of Arrhythmia Abnormal heart pulse formation Abnormal heart pulse conduction Classification of Arrhythmia Abnormal
More informationAcute Arrhythmias in the Hospitalized Patient
Acute Arrhythmias in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisc Disclosures Medtronic: Research Support
More informationAPPROACH TO TACHYARRYTHMIAS
APPROACH TO TACHYARRYTHMIAS PROF.DR.MD.ZAKIR HOSSAIN PROFESSOR AND HEAD DEPARTMENT OF MEDICINE SZMCH TACHYARRYTHMIA Cardiac arrythmia is a disturbance of electrical rhythm of heart. Cardac arrythmia with
More informationDual-Chamber Implantable Cardioverter-Defibrillator
February 1998 9 Dual-Chamber Implantable Cardioverter-Defibrillator A.SH. REVISHVILI A.N. Bakoulev Research Center for Cardiovascular Surgery, Russian Academy of Medical Sciences, Moscow, Russia Summary
More informationEndpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD
Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD Professor of Cardiology/Medicine Director of the Heart Research Follow Up Program, University of Rochester, Rochester,
More informationTreatment of Arrhythmias in the Emergency Setting
Treatment of Arrhythmias in the Emergency Setting Zian H. Tseng, M.D. Assistant Professor of Medicine Cardiac Electrophysiology Section Cardiology Division University of California, San Francisco There
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationJournal of the American College of Cardiology Vol. 41, No. 12, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00467-4
More informationOut-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry
European Heart Journal (2003) 24, 1204 1209 Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry Anton P.M. Gorgels*, Claudia Gijsbers, Jacqueline de
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationSyncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?
Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC
More informationAbbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationState of the art of ICD programming: Lessons learned and future directions
Neth Heart J (2014) 22:415 420 DOI 10.1007/s12471-014-0582-4 REVIEW ARTICLE State of the art of ICD programming: Lessons learned and future directions M. H. Mastenbroek & S. S. Pedersen & H. Versteeg &
More informationBrugada syndrome is a cardiac disease caused by an
Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome Bernard Belhassen, MD; Aharon Glick, MD; Sami Viskin, MD Background Automatic implantable cardioverter-defibrillator therapy is considered
More informationDifferent indications for pacemaker implantation are the following:
Patient Resources: ICD/Pacemaker Overview ICD/Pacemaker Overview What is a pacemaker? A pacemaker is a device that uses low energy electrical pulses to prompt the heart to beat whenever a pause in the
More informationICD Therapy in Survivors of Sudden Cardiac Death Awaiting Heart Transplantation
CD Therapy in Survivors of Sudden Cardiac Death Awaiting Heart Transplantation Michael Grimm, MD, Georg Grimm, MD, PhD, Andreas Zuckermann, MD, Georg Wieselthaler, MD, Michael Feuerstein, MS, Homayoun
More informationElectrophysiology. See page 1725
Journal of the American College of Cardiology Vol. 38, No. 6, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01597-2 Electrophysiology
More informationInvasive Risk Stratification: When is it needed?
Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of
More informationChapter 2. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Chapter 2 Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients Guido H. van Welsenes, MS, Johannes B. van Rees, MD, C. Jan Willem Borleffs, MD, PhD, Suzanne
More information